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Background: Previous reports have suggested that malignant transformations originate from adult stem cells, and
may thus express the stem-cell-associated markers. The purpose of this study is to investigate the differential
expression and clinical significance of seven stem-cell-associated markers (Bmi1, CD133, CD44, Sox2, Nanog, OCT4
and Msi2) in lung cancer, providing new targets for the diagnosis and treatment of lung cancer.
Methods: In this study, we evaluated the differential expression of mRNA levels seven stem-cell-associated markers
by semi-quantitative reverse transcription polymerase chain reaction (RT-PCR) from 112 human lung cancer and 18
non-cancer tissues obtained by bronchoscopy. We further verified the differential expression of these markers by
immunohistochemistry in 50 lung cancer specimens, 30 benign inflammatory lesion tissues and 20 non-tumor
adjacent lung tissues.
Results: With the exception of OCT4, other markers Bmi1, CD133, CD44, Sox2, Nanog and Msi2 mRNA and protein
were abundantly expressed in lung cancer. Additionally, Nanog expression was highly upregulated in lung cancer
tissues and rarely presented in non-cancerous lung tissues, the sensitivity and specificity of Nanog mRNA reached
63.4% and 66.7%, respectively. Nanog therefore possessed high diagnostic value, however, CD44, Bmi1 and CD133
showed poor diagnostic value in lung cancer.
Conclusion: Nanog may serve as a promising diagnostic marker of lung cancer and potential therapeutic target in
lung cancer.
Keywords: Stem-cell-associated marker, Lung cancer, Therapeutic target, Diagnostic markerBackground
Lung cancer is one of the leading causes of cancer-related
mortality in the world, and the incidence rates are increas-
ing in many countries [1]. Although the prognosis is im-
proving, the 5-year overall survival rate of lung cancer
patients is still only approximately 16% [2]. In order to im-
prove survival outcome, it is important to detect and surgi-
cally remove lung cancer at an early stage. Currently, the
cancer stem cell (CSC) theory proposes that tumors con-
tain a small subpopulation of CSC, which is responsible for
tumor growth, invasion and metastasis [3]. CSC and* Correspondence: mobiwen@yahoo.com
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reproduction in any medium, provided the ornormal tissue stem cells share important characteristics:
self-renewal, multipotency and unlimited proliferation,
and potentially overlapping molecular mechanisms [4,5].
In human adult tissues and tumors, several hundred stem-
cell-associated markers have been identified. In lung can-
cer, the common stem-cell-associated markers include
Bmi1, CD133, CD44, Sox2, OCT4 and so on [6,7]. Emer-
ging evidences showed that these stem-cell-associated
markers correlate with tumorigenesis, progression and
metastasis, and may be as potential diagnostic markers for
various human tumors [8-15].
Bmi1 is an oncogenic member of the polycomb group
proteins involved in the self-renewal and differentiation
of stem cells. The expression of Bmi1 mRNA has been
shown to be a good marker to support the diagnosis ofhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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wise, CD133, a transmembrane glycoprotein which was
first recognized in human hematopoietic stem cells, is
considered the most representative marker to isolate
CSC from lung cancer [9]. Recently, Moreira et al. [10]
found CD133 is expressed in 58% of small cell lung can-
cers and 19% of lung adenocarcinomas, but not in nor-
mal lung tissue, suggesting that CD133 could be used as
a potential diagnostic marker in lung cancer. Another
surface marker, CD44, has also been used to isolate CSC
from lung cancer [11]. A previous study using competi-
tive RT-PCR to detect the expression of CD44 in urine
for bladder cancer diagnosis was highly accurate and a
potential non-invasive diagnostic marker for bladder
cancer [12]. Transcription factors, Sox2, OCT4 and Nanog
form a core regulatory network of self-renewal and differ-
entiation in embryonic stem cells, which are essential in
sustaining stem cell pluripotency [13]. Recent reports show
that Sox2, OCT4 and Nanog are potential diagnostic
markers for lung cancer [14-16]. Additionally, Musashi2
(Msi2), a RNA binding protein, play crucial roles in
maintaining self-renewal and pluriopentency of embryonic
stem cells. It have been demonstrated to participate in
tumorigenesis and progression of multiple solid tumors
[17,18], and are expressed in lung cancer [10]. However,
these studies which are mainly based on surgical specimens
to screen for new molecular markers have certain limita-
tions in clinical application because most lung cancers are
unresectable.
Bronchoscopy has become an essential method by which
to analyze and diagnose lung cancer through technological
advances and its widespread application. Common bron-
choscopy techniques including forceps biopsy, brushing
and washing can easily obtained adequate specimens for
histological, cytological and molecular biological analysis
[19]. The purpose of this study is to investigate the differ-
ential and clinical significance of these stem-cell-associated
markers in bronchoscopy biopsy specimens.
In this study, we applied RT-PCR to examine the differ-
ential expression of Bmi1, CD133, CD44, Sox2, Nanog,
OCT4 and Msi2 mRNA in bronchoscopic biopsy speci-
mens from lung cancer and non-cancer patients. Further-
more immunohistochemistry was used to define the
localization and expression patterns of these stem-cell-as-
sociated proteins in surgically resected lung cancer and
non-malignant lung tissues. The diagnostic value of these
seven stem-cell-associated markers was evaluated in lung
cancer.Materials and methods
Clinical samples from bronchoscope biopsy
This prospective study in 112 patients with histologically
proven lung cancer and 18 non-cancer patients wasperformed at Guilin Medical University Hospital and Af-
filiated Nan Xi Shan Hospital in China from January, 2011
to January, 2012. These 112 lung cancer patients included
94 males and 18 females ranging from 29 to 80 years of
age (median = 59.2). Fifty-six cases were squamous cell car-
cinomas (SCC), 17 cases adenocarcinomas (Ad), 28 cases
small cell lung carcinomas (SCLC) and 11 cases of other
types of lung cancer. Based on clinical and radiological
findings, 100 cases had been evaluated for stages: 7 cases
of stage I, 6 cases of stage II, 60 cases of stage III and
27 cases of stage IV of lung cancer. Among 18 cases of
non-cancer, 7 cases were bronchitis, 7 cases tuberculosis,
3 cases pneumonia and 1 case brochiectasis. All patients
had not received any anti-cancer therapy before receiving
bronchoscopy. At least 5 biopsy specimens were obtained
from one patient. One to two specimens were snap frozen
and stored at -80°C for RT-PCR analysis under the condi-
tion of specimens were sufficient for routine diagnosis. The
remaining specimens were fixed in buffered formalin for
histopathological evaluation. This study was approved by
the Guilin Medical University Review Board, and informed
consent was obtained from all patients under the protocols
prescribed by the Guilin University Ethics Committee.Semi-quantitative RT-PCR
Total RNA was isolated from the biopsy tissue using Trizol
reagent (TakaRa Bio Inc, Dalian, China) according to the
manufacturer's instructions. One μg of the mRNA was re-
verse transcribed to cDNA using PrimeScript II 1st Strand
cDNA Synthesis Kit (TakaRa). One μl of the cDNA was
used in PCR for the amplification of β-actin and seven
stem-cell-associated markers. The primers are presented
in Table 1. The DNA thermal cycler conditions used were
94°C for 5 min (pre-denature), and 35 cycles of 94°C for
1 min, annealing for 30 s and extension at 72°C for 45 s,
followed by a final extension of 72°C for 2 min. Six μl of
each PCR-amplified product were separated on a 2% agar-
ose gel, which was then visualized by ethidium bromide
staining using a JS-780 Gel Image Analysis System (Peiqing
Sci Tech, Ltd, Shanghai, China). The ratio of integrated
density of target genes over corresponding β-actin was
normalized as relative mRNA expression levels of stem-
cell-associated markers.Immunohistochemistry (IHC)
A total of 50 cases of surgically resected lung cancer, 30
benign inflammatory lesion tissues and 20 normal or
non-tumor adjacent lung tissues were used for IHC experi-
ments. The lung cancer samples consisted of 17 adenocar-
cinomas (Ad), 3 bronchioloalveolar carcinomas (BAC), 23
squamous cell carcinomas (SCC) and 7 small cell lung car-
cinomas (SCLC). Thirty cases of benign inflammatory
Table 1 The primers and primary antibody used in this study
Gene
symbles
Primers for RT-PCR Antibodies for IHC
Primer sequences Annealing temperature (°C) Antibody sources Clone Dilution
Bmi1 Reverse 5’-ATT GTC TTT TCC GCC CGC TT-3’ 58.2 ProMab Biotechnologies Inc 3E3 1:800
Forward 5’-TGG CAT CAA TGA AGT ACC CTC-3’
CD44 Reverse 5’-TGC TAC TGA TTG TTT CAT TGC G-3’ 56.2 ProMab Biotechnologies Inc 8E2F3 1:30000
Forward 5’-GGA CCA GGC CCT ATT AAC CC-3’
CD133 Reverse 5’-AAA CAA TTC ACC AGC AAC GAG-3’ 54.1 ProMab Biotechnologies Inc 3 F10 1:400
Forward 5’-TAG TAC TTA GCC AGT TTT ACC G-3’
Sox2 Reverse 5’- GCT AGT CTC CAA GCG ACG AA-3’ 56.2 ProMab Biotechnologies Inc 10 F10 1:800
Forward 5’- TAC AGT CTA AAA CTT TTG CCC TT-3’
Nanog Reverse 5’-AGG CAA CTC ACT TTA TCC CAA-3’ 54.1 Cell signaling technology D73G4 1:300
Forward 5’-GAT TCT TTA CAG TCG GAT GCT T-3’
Oct-4 Reverse 5’-TGC AGA AAG AAC TCG AGC AA-3’ 56.2 Santa Cruz Biotechnology C-10 1:50
Forward 5’-CTC ACT CGG TTC TCG ATA CTG G-3’
Msi2 Reverse 5’-CAG ACC TCA CCA GAT AGC CTT-3’ 56.2 ProMab Biotechnologies Inc 2C11 1:1000
Forward 5’-TAC TGT GTT CGC AGA TAA CCC-3’
β-actin
(217 bp)
Reverse 5’GTG ACG TGG ACA TCC GCA AAG-3’ 60.2
Forward 5’-ATC CAC ATC TGC TGG AAG GTG GAC-3’
β-actin
(417 bp)
Reverse 5’-ACA GAG CCT CGC CTT TGC CGA TC-3’ 60.2
Forward 5’-TGG GTC ATC TTC TCG CGG TTG G-3’
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pneumonia, 6 cases of inflammatory pseudotumor, 3 cases
of brochiectasis, 2 cases of lung abscess and 1 case of be-
nign fibroma of lung. In 50 non-cancer lung tissues 3 cases
were squamous metaplasia including 2 cases of non-tumor
adjacent lung tissues and 1 case of pneumonia. In all patients
bronchoscopy and surgery were performed at Guilin Medical
University Hospital from January, 2002 to December, 2011.
None of the subjects received radiation therapy or chemo-
therapy before surgery.
Surgical specimens were fixed in 10% formaldehyde, and
paraffin-embedded. After deparaffinization and rehydration,
the 4 μm sections underwent antigen retrieval by boiling in
10 mM citrate buffer (pH 6.0) or EDTA (pH 8.0). The sec-
tions were immersed in H2O2 for 10 min and washed with
PBS three times. Then the sections were incubated for 1 hr
with the primary antibodies (Table 1) at 37°C. After a brief
wash, the sections were incubated for 20 min with Polymer
Helper (ZSGB-BIO, Beijing, China). Sections were washed
three times with PBS and the antigen was visualized
with polyperoxidase-anti-mouse/rabbit IgG (ZSGB-BIO)
and DAB as substrate (ZSGB-BIO). The sections were
counterstained with Mayer hematoxylin and mounted in
Permount. Blank controls were obtained by replacing the
primary antibodies with PBS.
The expression pattern criteria determined by IHC in-
cluded: ‘diffuse’ when almost all cells expressed the antigen;
‘focal’ when isolated groups of positive cells were seenwithin a histological section; ‘isolated staining’ when single
cells were positive for the marker. All slides were reviewed
by a pathologist (Lu JY, Guilin, China) and a well-trained
researcher in pathology (Li LD, Guilin, China) blinded to
the patients' clinical information.Statistical analysis
The Chi-Square test and the Mann–Whitney U test were
applied to compare the expression of markers between lung
cancer and non-cancer. The Chi-Square test was also
performed to analyze the association between mRNA ex-
pression markers and lung cancer clinical factors. For
evaluation of diagnostic value of seven stem-cell-associated
markers mRNA, the following calculations were made:
sensitivity (%) was calculated as true-positive/(true-posi-
tive +false-negative)×100, specificity (%) as true-negative/
(true-negative + false-positive)×100 and diagnostic accur-
acy (%) as (true-positive + true-negative/(true-positive +
false-negative + false-positive + true-negative)×100, where
true-positive denotes specimens with stem-cell-associated
marker positive expression and lung cancer diagnosis dur-
ing follow up, true-negative denotes negative expression
with no lung cancer, false-positive denotes positive expres-
sion with no lung cancer and false-negative denotes nega-
tive expression and diagnosed lung cancer. All statistical
analyses were performed by SPSS 17.0 software package
for Windows. P<0.05 was regarded statistically significant.
Table 2 mRNA expression of stem cell makers in human lung cancer and non-cancer lung tissues
Lung cancer Non-cancer P Lung cancer Non-cancer P
Positive rate, %(n) Positive rate, %(n) Expression, χ ± s Expression, χ ± s Value
Bmi1 88.4(99/112) 66.7(12/18) 0.026 0.60±0.73 0.32±0.29 0.118
CD133 85.7(96/112) 55.6(10/18) 0.006 0.77±0.90 0.58±0.97 0.057
CD44 98.2(110/112) 88.9(16/18) 0.092 1.67±1.77 1.44±1.33 0.606
Sox2 98.2(110/112) 83.3(15/18) 0.019 2.06±2.15 0.99±1.53 0.001
Nanog 63.4(71/112) 33.3(6/18) 0.016 0.23±0.42 0.04±0.09 0.013
OCT4 85.7(96/112) 38.8(7/18) <0.0001 0.46±0.50 0.12±0.27 <0.0001
Msi2 96.4(108/112) 94.4(17/18) 0.531 1.29±1.13 0.47±0.51 <0.0001
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The mRNA expression of seven stem-cell-associated
markers in biopsy samples obtained through
bronchoscopy
The expression of Bmi1, CD133, CD44, Sox2, Nanog,
OCT4 and Msi2 mRNA in bronchoscopic biopsies of
lung cancer and non-cancer patients are presented in
Table 2 and Figure 1. Overall, the mRNA expression of
seven markers was higher in the malignant group than
in the benign group. However, the mRNA relative levels
of Bmi1, CD133 and CD44 by RT-PCR were notFigure 1 Example RT-PCR bands of human lung cancer and non-lung
were isolated and reverse transcribed to cDNA from the biopsy tissues. RT-
2% agarose gels with ethidium bromide.significantly different between lung cancer and non-
malignant lung tissues analyzed by Mann–Whitney
U test, nor were the expression rates of CD44 and
Msi2. We found that the Bmi1 positive expression rate
was significantly correlated with histology types
(P=0.007) and differentiation (P=0.027), while the posi-
tive rate of Nanog was negatively correlated with differ-
entiation (0.032). However, the positive expression
rates of CD133, CD44, Sox2, OCT4 and Msi2 did not
correlate with age, gender, histological type, stage and
differentiation of lung cancer (Table 3).cancer biopsy tissues obtained from bronchoscopy. Total RNAs
PCR Products of β-actin and stem-cell-associated markers were run on











P* OCT4 expression P* MSi2 expression P*
cases Postive, n(%) Postive, n(%) Postive, n(%) Postive, n(%) Postive, n(%) Postive, n(%) Postive, n(%)
Age
<60 57 51(89.5) 0.716 48(84.2) 0.643 56(98.2) 1 55(96.5) 0.496 36(63.2) 0.958 47(82.5) 0.448 54(94.7) 0.618
≥60 55 48(87.3) 48(87.3) 54(98.2) 55(100) 35(63.6) 49(89.1) 54(98.2)
Gender
Male 94 84(89.4) 0.436 80(85.1) 1 92(97.9) 1 92(97.9) 1 57(60.6) 0.167 79(84.0) 0.462 90(95.7) 1
Female 18 15(83.3) 16(88.9) 18(100) 18(100) 14(77.8) 17(94.4) 18(100)
Histology
SCLC 28 27(96.4) 0.007 27(96.4) 0.066 26(92.9) 0.171 27(96.4) 1 22(78.6) 0.068 26(92.9) 0.601 27(96.4) 1
Ad 17 11(64.7) 16(94.1) 17(100) 17(100) 13(76.5) 14(82.4) 16(94.1)
SCC 56 52(92.9) 43(76.8) 56(100) 55(98.2) 31(55.4) 46(82.1) 54(96.4)
other 11 9(81.8) 10(90.9) 11(100) 11(100) 5(45.5) 10(90.9) 11(100)
Stage
I~II 13 13(100) 0.601 11(84.6) 1 13(100) 1 13(100) 1 7(53.8) 0.369 10(76.9) 0.407 13(100) 1
III~IV 87 78(89.7) 74(85.1) 85(97.7) 85(97.7) 58(66.7) 75(86.2) 84(96.6)
Differentiation
Well-Moderate 28 21(75) 0.027 21(75) 0.216 28(100) 1 27(96.4) 0.337 12(42.9) 0.032 22(78.6) 0.537 26(92.9) 0.262
Poor 55 52(94.5) 48(87.3) 55(100) 55(100) 37(67.3) 47(85.5) 54(96.4)

















Figure 2 Representative the expression of Bmi1, CD44, CD133, Sox2, Nanog, OCT4 and Msi2 in normal lung, benign lesion and lung
cancer. (A) Nuclear staining of Bmi1 is expressed (red arrows) in normal lung, benign fibroma of lung and squamous cell carcinomas.
(B) Membranous staining of CD44 in normal lung, benign fibroma of lung and squamous cell carcinomas. (C) Membranous and cytoplastic
staining of CD133 in normal bronchial epithelium cells and squamous cell carcinomas, negative immunostaining signal of CD133 in benign
fibroma of lung. (D) Nuclear staining of Sox2 in normal bronchial epithelium cells, squamous metaplasia and squamous cell carcinomas.
(E) Cytoplastic and nuclear staining of Msi2 in normal bronchial epithelium cells, squamous metaplasia and squamous cell carcinomas.
(F) Negative immunostaining signal of Nanog in normal lung, cytoplastic staining of Nanog in squamous metaplasia and squamous cell
carcinomas. (G). Negative immunostaining signal of OCT4 in normal lung and tuberculosis, nuclear staining of OCT4 in small cell lung carcinomas.
All images were taken at 400× magnification.
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Table 4 The specificity, accuracy and sensitivity of seven
stem-cell-associated markers mRNA in biopsy samples
obtained from bronchoscopy
Specificity, % Accuracy, % Sensitivity, %
Bmi1 33.3 80.8 88.4
CD133 44.4 80 85.7
CD44 11.1 86.2 98.2
Sox2 16.7 86.9 98.2
Nanog 66.7 63.8 63.4
OCT4 61.2 82.3 85.7
Msi2 5.6 83.8 96.4
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associated markers protein in non-malignant lung tissues
and lung cancer
Based on our RT-PCR results, most of the stem-cell-associ-
ated markers mRNA were expressed in non-malignant
lung tissues although the expression levels were relative
low. Therefore, we further examined the localization and
expression patterns of stem cell markers in non-malignant
lung tissues and lung cancer by IHC.
Bmi1 was diffusely expressed in bronchial epithelium
cells, alveolar epithelium cells, lung interstitial cells and
some inflammatory cells of all non-malignant lung tissues
(Figure 2A), and was diffusely expressed in 47 cases of lung
cancer and focally expressed in 1 case of Ad and 1 case of
SCLC (Figure 2A). Similar to Bmi1, CD44 was abundantly
expressed in alveolar epithelium cells, lung interstitial cells,
macrophages, inflammatory cells and metaplastic squa-
mous bronchial epithelium of non-malignant lung tissues
(Figure 2B), but was absent in normal bronchial epithelium
cells. 38 out of 50 lung cancer tissues were positive for
CD44, of which 37 cases were diffusely positive and 1 case
was focally positive expression (Figure 2B).
In non-malignant lung tissues, CD133 was exclusively
expressed in some, but not all, bronchial epithelium cells
and bronchial smooth muscle cells (Figure 2C). CD133+
bronchial epithelium cells were found in 74% of non-
malignant lung tissues while CD133+ bronchial smooth
muscle cells were 70%. In lung cancer tissues, about 56%
of tumor samples were diffusely positive, 8% focally posi-
tive and 2% isolated positive for CD133 (Figure 2C).
In non-malignant lung tissues, all bronchial epithelium
and squamous metaplasia showed positive expression of
Sox2 (Figure 2D) and Msi2 (Figure 2E), the expression de-
creases in terminal bronchioles and was absent in alveolar
epithelial. In lung cancer, the expression of Sox2 and Msi2
was 90% and 94% respectively, and more than 85% of
tissues was diffusely positive for both of the markers
(Figure 2D, E).
In non-malignant lung tissues, only 2 cases of squamous
metaplasia in non-tumor adjacent lung tissues were posi-
tive for Nanog (Figure 2F), whereas, Nanog staining wasdetected in 36 of 50 (72%) cases of lung cancer, in which
29 cases were diffusely positive, 6 cases were focally posi-
tive and 1 case was isolated positive (Figure 2F).
In all non-malignant lung tissues, no positivity for OCT4
was observed (Figure 2G). In lung cancer group, only one
case of SCC and one case of SCLC were focally positive for
OCT4 (Figure 2G).
Potential value of the expression of stem-cell-associated
markers as diagnostic markers
Table 4 describes the specificity, accuracy and sensitivity
of seven stem-cell-associated markers mRNA in bron-
choscopic biopsies of lung cancer and non-cancer pa-
tients. The stem-cell-associated markers with the
highest sensitivity for malignancy were CD44 (98.2%),
Sox2 (98.2%) and Msi2 (96.4%), but their specificity
were too low to be considered of no clinical signifi-
cance. Nanog exhibited the highest specificity which
was 66.7%, and its sensitivity was 63.4%.
Discussion
In the present study, we evaluated the differential expres-
sion of seven stem-cell-associated markers in broncho-
scopic biopsies of lung cancer and non-cancer patients by
RT-PCR, and assessed their diagnostic value potential.
Our data found Nanog mRNA had the highest specificity
in lung cancer. We further confirmed the high diagnostic
value of Nanog protein levels by IHC, Nanog was
overexpressed in lung cancer tissues, but rarely expressed
in non-malignant lung tissue. Taken together, these results
demonstrate that Nanog mRNA is a potential diagnostic
marker for lung cancer.
Nanog is a transcription factor that plays an important
role in maintaining self-renewal of embryonic stem cells.
Current studies have reported that the expression of
Nanog was higher in multiple cancerous tissues than in
their normal counterparts, including breast cancer [20],
gastric adenocarcinomas [21], colorectal cancer [22], gli-
omas [23] and ovarian serous cystadenocarcinomas [24]. In
this study, we found the expression of Nanog mRNA in
bronchoscopic biopsies of lung cancer patients was signifi-
cantly higher compared to that in non-cancer patients. Al-
though Nirasawa et al. [16] have also reported that the
expression of Nanog mRNA was higher in surgically
resected lung cancer tissues than in non-cancerous tissues,
it is not known what cells express Nanog in non-cancerous
lung tissues. Using IHC, we found Nanog was only
expressed in metaplastic squamous bronchial epithelium
cells in 2 out of 50 non-malignant lung tissues, and was
negative in normal airway epithelia. Therefore, Nanog may
be a good diagnostic marker for lung cancer.
In this study, our results showed that the mRNA levels
of Bmi1, CD44 and CD133 were not significantly different
between lung cancer and non-malignant lung tissues.
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and CD133 were not only expressed in lung cancers, Bmi1
and CD44 were also abundantly expressed in lung intersti-
tial cells, inflammatory cells and bronchial epithelium
cells, and CD133 was diffusely expressed in some normal
bronchial epithelium cells and bronchial smooth muscle
cells, consistent with previous studies [11,25,26]. Hence,
Bmi1, CD44 and CD133 are poor diagnostic markers for
lung cancer.
Likewise, although the expression levels of Sox2 and
Msi2 mRNA in lung cancer tissues were significantly
higher as compared with non-malignant tissues, we found
more than 80% of bronchoscopic biopsy specimens of
non-cancer patients were positive for Sox2 and Msi2
mRNA, and all non-malignant tissues were positive for
Sox2 and Msi2 protein expression, consistent with previ-
ous findings [10,27,28]. Therefore, Sox2 and Msi2 have
poor diagnostic specificity in lung cancer.
It is still controversial whether lung cancer cells ex-
press OCT4. Some researchers believe that OCT4 is in-
volved in tumorigenesis and metastasis of lung cancer,
and therefore is a potential diagnostic marker and use-
ful therapeutic target of lung cancer [9,15,29], while
others did not detect OCT4 expression in lung cancer
[10,30]. Although we observed OCT4 mRNA expres-
sion in 85.7% of lung cancer and 38.8% of non-cancer
bronchoscopic biopsy specimens, but OCT4 protein
was nearly absent in 50 cases of lung cancer tissues.
The reason for this discrepancy is unclear, but may be
due to complex mechanism of post-transcriptional
regulation, or potential presence of unknown OCT4
pseudogenes which cause false positive detection by
RT-PCR. Therefore, the diagnostic value of OCT4
mRNA in bronchoscopic biopsy specimens requires
further investigation.
In addition, we examined the correlation of seven
stem cell markers expression in bronchoscopic biopsy
specimens of lung cancer with patient clinical features.
As we know, poorly differentiated cancers show stron-
ger aggressive and metastatic ability [21]. We found the
positive expression rates of Nanog and Bmi1 mRNA
was inversely correlated to differentiation of lung can-
cer, indicating these two markers may be useful to pre-
dict tumor progression and poor prognosis in lung
cancer. Chiou et al. [29] reported that Nanog expres-
sion in surgically resected lung cancer tissues is an in-
dependent prognostic factors of poor prognosis for
patients. Vrzalikova and colleagues [31] also believed
that the expression of Bmi1 in surgically resected lung
cancer tissues is a prognostic marker in lung cancer.
However, surgical resection is not an option for all lung
cancer patients, and therefore the use of these markers
in bronchoscopic biopsies to predict prognosis would
be a great clinical advantage.Conclusions
In conclusion, the expression of Nanog mRNA in bron-
choscopic biopsy specimens is useful diagnostic marker
for lung cancer. Further investigation of the diagnostic
potential of Nanog in early stages of lung cancer may
have a profound clinical impact.
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